Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, Smith G. Tian JH, et al. Among authors: maciejewski s. Nat Commun. 2021 Jan 14;12(1):372. doi: 10.1038/s41467-020-20653-8. Nat Commun. 2021. PMID: 33446655 Free PMC article.
Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.
Gorman MJ, Patel N, Guebre-Xabier M, Zhu A, Atyeo C, Pullen KM, Loos C, Goez-Gazi Y, Carrion R Jr, Tian JH, Yaun D, Bowman K, Zhou B, Maciejewski S, McGrath ME, Logue J, Frieman MB, Montefiori D, Mann C, Schendel S, Amanat F, Krammer F, Saphire EO, Lauffenburger D, Greene AM, Portnoff AD, Massare MJ, Ellingsworth L, Glenn G, Smith G, Alter G. Gorman MJ, et al. Among authors: maciejewski s. bioRxiv [Preprint]. 2021 Feb 5:2021.02.05.429759. doi: 10.1101/2021.02.05.429759. bioRxiv. 2021. PMID: 33564763 Free PMC article. Updated. Preprint.
Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.
Alter G, Gorman M, Patel N, Guebre-Xabier M, Zhu A, Atyeo C, Pullen K, Loos C, Goez-Gazi Y, Carrion R Jr, Tian JH, Yuan D, Bowman K, Zhou B, Maciejewski S, McGrath M, Logue J, Frieman M, Montefiori D, Schendel S, Saphire EO, Lauffenburger D, Greene A, Portnoff A, Massare M, Ellingsworth L, Glenn G, Smith G, Mann C, Amanat F, Krammer F. Alter G, et al. Among authors: maciejewski s. Res Sq [Preprint]. 2021 Feb 15:rs.3.rs-200342. doi: 10.21203/rs.3.rs-200342/v1. Res Sq. 2021. PMID: 33619473 Free PMC article. Updated. Preprint.
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination.
Gorman MJ, Patel N, Guebre-Xabier M, Zhu AL, Atyeo C, Pullen KM, Loos C, Goez-Gazi Y, Carrion R Jr, Tian JH, Yuan D, Bowman KA, Zhou B, Maciejewski S, McGrath ME, Logue J, Frieman MB, Montefiori D, Mann C, Schendel S, Amanat F, Krammer F, Saphire EO, Lauffenburger DA, Greene AM, Portnoff AD, Massare MJ, Ellingsworth L, Glenn G, Smith G, Alter G. Gorman MJ, et al. Among authors: maciejewski s. Cell Rep Med. 2021 Sep 21;2(9):100405. doi: 10.1016/j.xcrm.2021.100405. Epub 2021 Aug 31. Cell Rep Med. 2021. PMID: 34485950 Free PMC article.
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, McFall H, Robinson M, Plested JS, Zhu M, Cloney-Clark S, Zhou B, Chau G, Robertson A, Maciejewski S, Hammond HL, Baracco L, Logue J, Frieman MB, Smith G, Patel N, Glenn GM; Novavax 2019nCoV101 Study Group. Mallory RM, et al. Among authors: maciejewski s. Lancet Infect Dis. 2022 Nov;22(11):1565-1576. doi: 10.1016/S1473-3099(22)00420-0. Epub 2022 Aug 10. Lancet Infect Dis. 2022. PMID: 35963274 Free PMC article. Clinical Trial.
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants.
Logue J, Johnson RM, Patel N, Zhou B, Maciejewski S, Foreman B, Zhou H, Portnoff AD, Tian JH, Rehman A, McGrath ME, Haupt RE, Weston SM, Baracco L, Hammond H, Guebre-Xabier M, Dillen C, Madhangi M, Greene AM, Massare MJ, Glenn GM, Smith G, Frieman MB. Logue J, et al. Among authors: maciejewski s. Nat Commun. 2023 Feb 28;14(1):1130. doi: 10.1038/s41467-022-35606-6. Nat Commun. 2023. PMID: 36854666 Free PMC article.
Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality.
Maciejewski S, Ruckwardt TJ, Morabito KM, Foreman BM, Burgomaster KE, Gordon DN, Pelc RS, DeMaso CR, Ko SY, Fisher BE, Yang ES, Nair D, Foulds KE, Todd JP, Kong WP, Roy V, Aleshnick M, Speer SD, Bourne N, Barrett AD, Nason MC, Roederer M, Gaudinski MR, Chen GL, Dowd KA, Ledgerwood JE, Alter G, Mascola JR, Graham BS, Pierson TC. Maciejewski S, et al. Sci Transl Med. 2020 Jun 10;12(547):eaaw9066. doi: 10.1126/scitranslmed.aaw9066. Sci Transl Med. 2020. PMID: 32522807
Limited Flavivirus Cross-Reactive Antibody Responses Elicited by a Zika Virus Deoxyribonucleic Acid Vaccine Candidate in Humans.
Burgomaster KE, Foreman BM, Aleshnick MA, Larman BC, Gordon DN, Maciejewski S, Morabito KM, Ledgerwood JE, Gaudinski MR, Chen GL, Mascola JR, Debbink K, Dowd KA, Graham BS, Pierson TC. Burgomaster KE, et al. Among authors: maciejewski s. J Infect Dis. 2021 Nov 16;224(9):1550-1555. doi: 10.1093/infdis/jiab185. J Infect Dis. 2021. PMID: 33961055 Free PMC article.
Cross-Reactive Flavivirus Antibody: Friend and Foe?
Maciejewski S, Pierson TC. Maciejewski S, et al. Cell Host Microbe. 2018 Nov 14;24(5):622-624. doi: 10.1016/j.chom.2018.10.016. Cell Host Microbe. 2018. PMID: 30439339 Free article.
48 results